Annual FCF
-$5.90 M
+$5.49 M+48.17%
31 December 2023
Summary:
Tenax Therapeutics annual free cash flow is currently -$5.90 million, with the most recent change of +$5.49 million (+48.17%) on 31 December 2023. During the last 3 years, it has risen by +$4.96 million (+45.65%). TENX annual FCF is now -924.02% below its all-time high of -$576.50 thousand, reached on 30 April 1998.TENX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$3.09 M
-$56.20 K-1.85%
30 September 2024
Summary:
Tenax Therapeutics quarterly free cash flow is currently -$3.09 million, with the most recent change of -$56.20 thousand (-1.85%) on 30 September 2024. Over the past year, it has dropped by -$1.91 million (-162.86%). TENX quarterly FCF is now -132.08% below its all-time high of $9.62 million, reached on 30 April 2002.TENX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$12.46 M
-$1.01 M-8.79%
30 September 2024
Summary:
Tenax Therapeutics TTM free cash flow is currently -$12.46 million, with the most recent change of -$1.01 million (-8.79%) on 30 September 2024. Over the past year, it has dropped by -$6.55 million (-111.03%). TENX TTM FCF is now -259.07% below its all-time high of $7.83 million, reached on 31 January 2003.TENX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TENX Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -162.9% | -111.0% |
| 3 y3 years | +45.6% | -11.4% | -14.7% |
| 5 y5 years | +21.9% | -78.8% | -64.8% |
TENX Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +48.2% | -234.5% | +40.2% | -111.0% | +0.1% |
| 5 y | 5 years | at high | +48.2% | -234.5% | +40.2% | -111.0% | +0.1% |
| alltime | all time | -924.0% | +62.8% | -132.1% | +71.4% | -259.1% | +26.8% |
Tenax Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$3.09 M(+1.9%) | -$12.46 M(+8.8%) |
| June 2024 | - | -$3.03 M(-41.3%) | -$11.45 M(+22.6%) |
| Mar 2024 | - | -$5.17 M(+339.8%) | -$9.34 M(+58.3%) |
| Dec 2023 | -$5.90 M(-48.2%) | -$1.17 M(-43.6%) | -$5.90 M(-8.0%) |
| Sept 2023 | - | -$2.08 M(+125.5%) | -$6.41 M(-16.3%) |
| June 2023 | - | -$923.00 K(-46.5%) | -$7.66 M(-24.7%) |
| Mar 2023 | - | -$1.72 M(+2.4%) | -$10.17 M(-10.7%) |
| Dec 2022 | -$11.39 M(+4.9%) | -$1.68 M(-49.4%) | -$11.39 M(-8.7%) |
| Sept 2022 | - | -$3.33 M(-2.9%) | -$12.48 M(+2.5%) |
| June 2022 | - | -$3.43 M(+16.5%) | -$12.17 M(+15.0%) |
| Mar 2022 | - | -$2.94 M(+6.3%) | -$10.58 M(-2.6%) |
| Dec 2021 | -$10.86 M(+17.1%) | -$2.77 M(-8.4%) | -$10.86 M(+7.8%) |
| Sept 2021 | - | -$3.02 M(+63.7%) | -$10.08 M(+6.8%) |
| June 2021 | - | -$1.85 M(-42.7%) | -$9.44 M(-3.9%) |
| Mar 2021 | - | -$3.22 M(+62.1%) | -$9.82 M(+5.9%) |
| Dec 2020 | -$9.28 M(+22.7%) | -$1.99 M(-16.7%) | -$9.27 M(+2.9%) |
| Sept 2020 | - | -$2.39 M(+7.0%) | -$9.01 M(+7.2%) |
| June 2020 | - | -$2.23 M(-16.6%) | -$8.41 M(+3.9%) |
| Mar 2020 | - | -$2.67 M(+54.7%) | -$8.09 M(+7.1%) |
| Dec 2019 | -$7.56 M(+37.3%) | -$1.73 M(-3.1%) | -$7.56 M(+7.5%) |
| Sept 2019 | - | -$1.78 M(-6.9%) | -$7.03 M(+3.3%) |
| June 2019 | - | -$1.91 M(-10.4%) | -$6.81 M(+11.9%) |
| Mar 2019 | - | -$2.14 M(+78.1%) | -$6.08 M(+10.4%) |
| Dec 2018 | -$5.51 M(-54.7%) | -$1.20 M(-22.9%) | -$5.51 M(-1.5%) |
| Sept 2018 | - | -$1.56 M(+30.7%) | -$5.59 M(+6.2%) |
| June 2018 | - | -$1.19 M(-23.8%) | -$5.26 M(-45.6%) |
| Mar 2018 | - | -$1.56 M(+21.8%) | -$9.67 M(-20.4%) |
| Dec 2017 | -$12.15 M(-23.5%) | -$1.28 M(+4.5%) | -$12.15 M(-13.1%) |
| Sept 2017 | - | -$1.23 M(-78.1%) | -$13.97 M(-17.9%) |
| June 2017 | - | -$5.60 M(+38.5%) | -$17.02 M(+2.6%) |
| Mar 2017 | - | -$4.04 M(+30.1%) | -$16.59 M(+4.5%) |
| Dec 2016 | -$15.87 M(+77.0%) | -$3.11 M(-27.5%) | -$15.87 M(+24.3%) |
| Sept 2016 | - | -$4.28 M(-17.1%) | -$12.77 M(+14.1%) |
| June 2016 | - | -$5.17 M(+55.5%) | -$11.19 M(+13.2%) |
| Mar 2016 | - | -$3.32 M(+23.0%) | -$9.88 M(-29.5%) |
| Dec 2015 | -$8.97 M(-9.0%) | - | - |
| Oct 2015 | - | -$2.70 M(-30.0%) | -$14.02 M(-1.8%) |
| July 2015 | - | -$3.86 M(+135.0%) | -$14.28 M(+15.0%) |
| Apr 2015 | -$9.86 M(+4.8%) | -$1.64 M(-35.8%) | -$12.42 M(+15.2%) |
| Mar 2015 | - | -$2.56 M(-21.5%) | -$10.77 M(-4.1%) |
| Jan 2015 | - | -$3.26 M(+10.0%) | -$11.23 M(+4.7%) |
| Oct 2014 | - | -$2.96 M(+48.3%) | -$10.72 M(+9.3%) |
| July 2014 | - | -$2.00 M(-33.7%) | -$9.81 M(+4.3%) |
| Apr 2014 | -$9.41 M(+85.5%) | -$3.01 M(+9.6%) | -$9.41 M(+19.4%) |
| Jan 2014 | - | -$2.75 M(+34.2%) | -$7.88 M(+33.4%) |
| Oct 2013 | - | -$2.05 M(+28.4%) | -$5.91 M(+17.6%) |
| July 2013 | - | -$1.60 M(+7.4%) | -$5.02 M(-1.0%) |
| Apr 2013 | -$5.07 M(-40.6%) | -$1.49 M(+92.0%) | -$5.07 M(+0.1%) |
| Jan 2013 | - | -$774.20 K(-33.6%) | -$5.07 M(-23.4%) |
| Oct 2012 | - | -$1.17 M(-29.2%) | -$6.61 M(-17.9%) |
| July 2012 | - | -$1.65 M(+11.4%) | -$8.05 M(-5.8%) |
| Apr 2012 | -$8.54 M | -$1.48 M(-36.2%) | -$8.54 M(-4.1%) |
| Jan 2012 | - | -$2.32 M(-10.9%) | -$8.91 M(-0.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Oct 2011 | - | -$2.60 M(+21.7%) | -$8.96 M(+8.9%) |
| July 2011 | - | -$2.14 M(+16.1%) | -$8.24 M(-7.1%) |
| Apr 2011 | -$8.87 M(-2.9%) | -$1.84 M(-22.4%) | -$8.87 M(-6.4%) |
| Jan 2011 | - | -$2.38 M(+26.8%) | -$9.48 M(-11.5%) |
| Oct 2010 | - | -$1.87 M(-32.4%) | -$10.71 M(+4.1%) |
| July 2010 | - | -$2.77 M(+13.1%) | -$10.29 M(+12.7%) |
| Apr 2010 | -$9.13 M(+106.3%) | -$2.45 M(-32.0%) | -$9.13 M(+12.4%) |
| Jan 2010 | - | -$3.61 M(+147.9%) | -$8.12 M(+44.1%) |
| Oct 2009 | - | -$1.46 M(-9.9%) | -$5.64 M(+9.5%) |
| July 2009 | - | -$1.61 M(+11.8%) | -$5.15 M(+16.3%) |
| Apr 2009 | -$4.42 M(+86.1%) | -$1.44 M(+28.7%) | -$4.42 M(+18.8%) |
| Jan 2009 | - | -$1.12 M(+16.1%) | -$3.73 M(-1.2%) |
| Oct 2008 | - | -$966.40 K(+8.4%) | -$3.77 M(+17.1%) |
| July 2008 | - | -$891.60 K(+19.5%) | -$3.22 M(+35.4%) |
| Apr 2008 | -$2.38 M(+109.0%) | -$745.80 K(-36.1%) | -$2.38 M(+32.6%) |
| Jan 2008 | - | -$1.17 M(+180.8%) | -$1.79 M(+60.4%) |
| Oct 2007 | - | -$415.90 K(+752.3%) | -$1.12 M(+17.6%) |
| July 2007 | - | -$48.80 K(-69.8%) | -$951.20 K(-16.4%) |
| Apr 2007 | -$1.14 M(-47.6%) | -$161.70 K(-67.1%) | -$1.14 M(-11.8%) |
| Jan 2007 | - | -$491.90 K(+97.7%) | -$1.29 M(-4.2%) |
| Oct 2006 | - | -$248.80 K(+5.8%) | -$1.35 M(-18.8%) |
| July 2006 | - | -$235.20 K(-25.0%) | -$1.66 M(-23.6%) |
| Apr 2006 | -$2.17 M(+5.3%) | -$313.70 K(-42.8%) | -$2.17 M(-11.7%) |
| Jan 2006 | - | -$548.80 K(-2.0%) | -$2.46 M(-4.8%) |
| Oct 2005 | - | -$559.80 K(-25.1%) | -$2.58 M(+5.7%) |
| July 2005 | - | -$747.80 K(+24.5%) | -$2.44 M(+18.5%) |
| Apr 2005 | -$2.06 M(+11.2%) | -$600.70 K(-10.8%) | -$2.06 M(+4.6%) |
| Jan 2005 | - | -$673.60 K(+60.2%) | -$1.97 M(+8.3%) |
| Oct 2004 | - | -$420.50 K(+14.6%) | -$1.82 M(-1.2%) |
| July 2004 | - | -$366.80 K(-28.0%) | -$1.84 M(-0.6%) |
| Apr 2004 | -$1.85 M(-13.0%) | -$509.40 K(-2.6%) | -$1.85 M(+10.0%) |
| Jan 2004 | - | -$522.90 K(+17.9%) | -$1.69 M(+2.3%) |
| Oct 2003 | - | -$443.50 K(+17.3%) | -$1.65 M(-23.4%) |
| July 2003 | - | -$378.20 K(+10.7%) | -$2.15 M(+1.0%) |
| Apr 2003 | -$2.13 M(-6.3%) | -$341.60 K(-29.6%) | -$2.13 M(-127.2%) |
| Jan 2003 | - | -$485.50 K(-48.7%) | $7.83 M(-414.5%) |
| Oct 2002 | - | -$947.30 K(+165.1%) | -$2.49 M(+21.5%) |
| July 2002 | - | -$357.30 K(-103.7%) | -$2.05 M(-9.9%) |
| Apr 2002 | -$2.27 M(+27.9%) | $9.62 M(-189.0%) | -$2.27 M(-81.7%) |
| Jan 2002 | - | -$10.81 M(+2035.5%) | -$12.40 M(+480.6%) |
| Oct 2001 | - | -$506.10 K(-13.2%) | -$2.13 M(+3.9%) |
| July 2001 | - | -$582.80 K(+16.7%) | -$2.05 M(+15.6%) |
| Apr 2001 | -$1.78 M(+91.0%) | -$499.40 K(-8.7%) | -$1.78 M(+11.7%) |
| Jan 2001 | - | -$546.70 K(+28.5%) | -$1.59 M(+18.3%) |
| Oct 2000 | - | -$425.60 K(+39.0%) | -$1.35 M(+31.9%) |
| July 2000 | - | -$306.20 K(-2.3%) | -$1.02 M(+11.6%) |
| Apr 2000 | -$931.00 K(+16.4%) | -$313.30 K(+4.4%) | -$913.30 K(+52.2%) |
| Jan 2000 | - | -$300.00 K(+200.0%) | -$600.00 K(+100.0%) |
| Oct 1999 | - | -$100.00 K(-50.0%) | -$300.00 K(+50.0%) |
| July 1999 | - | -$200.00 K | -$200.00 K |
| Apr 1999 | -$800.00 K(+38.8%) | - | - |
| Apr 1998 | -$576.50 K(-34.1%) | - | - |
| Apr 1997 | -$874.30 K(-44.1%) | - | - |
| Apr 1996 | -$1.56 M | - | - |
FAQ
- What is Tenax Therapeutics annual free cash flow?
- What is the all time high annual FCF for Tenax Therapeutics?
- What is Tenax Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Tenax Therapeutics?
- What is Tenax Therapeutics quarterly FCF year-on-year change?
- What is Tenax Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Tenax Therapeutics?
- What is Tenax Therapeutics TTM FCF year-on-year change?
What is Tenax Therapeutics annual free cash flow?
The current annual FCF of TENX is -$5.90 M
What is the all time high annual FCF for Tenax Therapeutics?
Tenax Therapeutics all-time high annual free cash flow is -$576.50 K
What is Tenax Therapeutics quarterly free cash flow?
The current quarterly FCF of TENX is -$3.09 M
What is the all time high quarterly FCF for Tenax Therapeutics?
Tenax Therapeutics all-time high quarterly free cash flow is $9.62 M
What is Tenax Therapeutics quarterly FCF year-on-year change?
Over the past year, TENX quarterly free cash flow has changed by -$1.91 M (-162.86%)
What is Tenax Therapeutics TTM free cash flow?
The current TTM FCF of TENX is -$12.46 M
What is the all time high TTM FCF for Tenax Therapeutics?
Tenax Therapeutics all-time high TTM free cash flow is $7.83 M
What is Tenax Therapeutics TTM FCF year-on-year change?
Over the past year, TENX TTM free cash flow has changed by -$6.55 M (-111.03%)